Who is sponsoring NCT04091529?

NCT04091529 is sponsored by International Evangelical Hospital.

What drugs are being tested in NCT04091529?

Interventions in NCT04091529: RADIOFREQUENCY ABLATION OF UTERINE MYOMAS.

What condition does NCT04091529 study?

NCT04091529 studies Uterine Fibroids.

Is NCT04091529 still recruiting?

NCT04091529 is currently completed. Last updated 18 September 2019.

Last reviewed 2019-09-18 · How we verify

NCT04091529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tailored Radiofrequency Ablation of Uterine Myomas

Completed NA Last updated 18 September 2019

What this trial tests

NA trial testing RADIOFREQUENCY ABLATION OF UTERINE MYOMAS in Uterine Fibroids in 54 participants. Completed in 31 March 2019.

Timeline

1 March 2017

Primary endpoint
1 March 2019

31 March 2019

Quick facts

Lead sponsor	International Evangelical Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	1 March 2017
Primary completion	1 March 2019
Estimated completion	31 March 2019
Sites	1 location across Italy

Drugs / interventions tested

RADIOFREQUENCY ABLATION OF UTERINE MYOMAS

Conditions studied

Uterine Fibroids — all drugs for Uterine Fibroids →

Sponsor

International Evangelical Hospital

Who can join

Adults 30 to 62, female only, with Uterine Fibroids. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To perform the use of radiofrequency myolysis (RFM) for the treatment of intra-uterine fibroids through less invasive access by combining trans-vaginal ultrasound, hysteroscopy and laparoscopy

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Prospective Intervention Trial on Tailored Radiofrequency Ablation of Uterine Myomas.
Fasciani A, Turtulici G, Siri G, Ferrero S, et al · · 2020 · cited 7× · PMID 32178351 · DOI 10.3390/medicina56030122

Verify or expand the search:

Other recruiting trials for Uterine Fibroids

Currently open trials in the same condition.

NCT07378098 — to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia · Phase 3 · recruiting
NCT07486622 — Transvaginal Electromechanical Fragmentation and Removal of Large Uterus in a Sealed Bag: The First Group of Clinical St · active not recruiting
NCT06671548 — Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids · Phase 3 · recruiting
NCT05448365 — Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid · NA · recruiting
NCT04126824 — Effect of Addition of Steroids on Duration of Analgesia · EARLY_PHASE1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04091529 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by International Evangelical Hospital
Last refreshed: 18 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04091529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing